 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...476477478479480481482483484485486...522523» |
- | Journal: Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies. (Pubmed Central) - Mar 25, 2017
Prior to cycle 1, patients were more likely to undergo routine diagnostic procedures compared to subsequent cycles. Efforts to perform routine procedures prior to admission may reduce hospital length of stay and costs.
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial primary completion date: Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell (clinicaltrials.gov) - Mar 24, 2017
P=N/A, N=150, Recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
Efforts to perform routine procedures prior to admission may reduce hospital length of stay and costs. Trial primary completion date: Jan 2017 --> Jan 2018
- | paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Review, Journal: Nanotechnology applications in thoracic surgery. (Pubmed Central) - Mar 24, 2017
Although early nanotechnology-based delivery systems show promise, the next frontier in lung cancer therapy is the development of 'theranostic' multifunctional NPs capable of integrating diagnosis, drug monitoring, tumour targeting and controlled drug release into various unifying platforms. This article provides an overview of key existing and emerging nanotechnology platforms that may find clinical application in thoracic surgery in the near future.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Antioxidant and antitumor activities of Capparis spinosa L. and the related mechanisms. (Pubmed Central) - Mar 24, 2017
In order to further research this finding, the present study investigate the blood biochemical indices, injury, energy metabolism, oxidative damage and mitochondrial membrane potential (Δψm) level of cardiac cells to study the effect of CSE on doxorubicin-induced cardiac toxicity...The regulatory mechanism of HepG2 cell apoptosis induced by CSQAH involved the increase in Ca2+ concentration and ROS levels, a decrease in Ca2+-Mg2+-ATPase activity in the HepG2 cells, and downregulation of anti-apoptotic Bcl-2 expression, and upregulation of apoptotic Bax expression. In summary, the present study demonstrated the antioxidant and antitumor activities of CSE which may suppress tumor growth and alleviate the side-effects of DOX, which may facilitate tumor treatment in a dual manner.
- | Trial completion, Trial primary completion date: Combination Chemotherapy in Treating Patients With Sarcoma (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=120, Completed, Sponsor: Mayo Clinic
In summary, the present study demonstrated the antioxidant and antitumor activities of CSE which may suppress tumor growth and alleviate the side-effects of DOX, which may facilitate tumor treatment in a dual manner. Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Oct 2013
- | doxorubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Cardiac Fibrosis by CMR in Patients With Cancer (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=10, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Oct 2013 Recruiting --> Completed | N=77 --> 10 | Trial primary completion date: Nov 2019 --> Jan 2017
- | Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 20, 2017
P2, N=22, Recruiting, Sponsor: University of Miami
Recruiting --> Completed | N=77 --> 10 | Trial primary completion date: Nov 2019 --> Jan 2017 Trial primary completion date: Dec 2017 --> Dec 2019
- | Trial termination, Trial primary completion date: Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma (clinicaltrials.gov) - Mar 20, 2017
P2, N=200, Terminated, Sponsor: American College of Radiology Imaging Network
Trial primary completion date: Dec 2017 --> Dec 2019 Recruiting --> Terminated | Trial primary completion date: Jun 2021 --> Jan 2014; slow accrual
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment change, Trial initiation date, Trial termination, Trial primary completion date: FIL-GALILEO: Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. (clinicaltrials.gov) - Mar 20, 2017
P2, N=1, Terminated, Sponsor: Fondazione Italiana Linfomi ONLUS
Recruiting --> Terminated | Trial primary completion date: Jun 2021 --> Jan 2014; slow accrual N=90 --> 1 | Initiation date: Jun 2016 --> Sep 2016 | Recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Feb 2017; GA101-CHOP not advantage from rituximab-CHOP
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Combination therapy: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome (clinicaltrials.gov) - Mar 17, 2017
P2, N=20, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=90 --> 1 | Initiation date: Jun 2016 --> Sep 2016 | Recruiting --> Terminated | Trial primary completion date: Jul 2020 --> Feb 2017; GA101-CHOP not advantage from rituximab-CHOP Not yet recruiting --> Recruiting
- | tamoxifen / Generic mfg., Nexavar (sorafenib) / Bayer, Amgen
Journal: Role of Imaging in Management of Desmoid-type Fibromatosis: A Primer for Radiologists. (Pubmed Central) - Mar 17, 2017
Response to systemic treatment with anti-inflammatory agents, hormonal therapy (eg, tamoxifen), cytotoxic chemotherapy (eg, doxorubicin, vinblastine, methotrexate), and targeted therapy (eg, sorafenib), as well as to radiation therapy, can be assessed at CT by monitoring size and attenuation changes or at MR imaging by monitoring size, T2 signal intensity, and degree of enhancement. Imaging also helps in detecting complications associated with systemic therapy and radiation therapy.
- | Herceptin (trastuzumab) / Roche
Journal: Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. (Pubmed Central) - Mar 17, 2017
P3
Patients who are homozygous for phenylalanine at this position represent a considerable proportion of the population and, in contrast to previously reported analyses from similarly designed trials, our results indicate that trastuzumab may be less efficacious in these patients. clinicaltrials.gov Identifier for NSABP B-31: NCT00004067.
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) (clinicaltrials.gov) - Mar 16, 2017
P3, N=855, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
clinicaltrials.gov Identifier for NSABP B-31: NCT00004067. Not yet recruiting --> Recruiting
- | doxorubicin hydrochloride / Generic mfg.
Journal: Doxorubicin-modified magnetic nanoparticles as a drug delivery system for magnetic resonance imaging-monitoring magnet-enhancing tumor chemotherapy. (Pubmed Central) - Mar 15, 2017
The in vivo experiments also showed that this drug delivery system combined with a local magnetic field could reduce the side effects of cardiotoxicity and hepatotoxicity. The results showed that the developed SPIO-PEG-D nanoparticles own a great potential for MRI-monitoring magnet-enhancing tumor chemotherapy.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Experimental Study of Magnetic Multi-Walled Carbon Nanotube-Doxorubicin Conjugate in a Lymph Node Metastatic Model of Breast Cancer. (Pubmed Central) - Mar 15, 2017
RESULTS Although no significant difference was found between the effects of doxorubicin and magnetic multi-walled carbon nanotube-doxorubicin with the same concentration of doxorubicin on EMT-6 breast cancer cells in vitro, in terms of sizes of metastatic lymph nodes and xenograft tumors, apoptosis in metastatic lymph nodes, and adverse reactions, the magnetic multi-walled carbon nanotube-doxorubicin group differed significantly from the other groups. CONCLUSIONS The magnetic multi-walled carbon nanotube-doxorubicin clearly played an inhibitory role in lymph node metastases to EMT-6 breast cancer cells.
- | paclitaxel / Generic mfg.
Journal: Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. (Pubmed Central) - Mar 15, 2017
However, omission of G-CSF was not associated with treatment delays or adverse events. Prospective studies are warranted to formally test whether routine G-CSF is necessary during dose-dense T therapy.
- || Xpovio (selinexor) / Karyopharm
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (clinicaltrials.gov) - Mar 14, 2017
P1, N=142, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Prospective studies are warranted to formally test whether routine G-CSF is necessary during dose-dense T therapy. Recruiting --> Active, not recruiting | N=470 --> 142 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: Surgery in Treating Children With Neuroblastoma (clinicaltrials.gov) - Mar 13, 2017
P3, N=968, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting | N=470 --> 142 | Trial primary completion date: Jun 2018 --> Jun 2019 Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion, Trial initiation date: A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma (clinicaltrials.gov) - Mar 13, 2017
P2, N=27, Completed, Sponsor: Lymphoma Study Association
Active, not recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Sep 2005 --> Dec 2005
- || Enrollment change, Combination therapy: Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer (clinicaltrials.gov) - Mar 13, 2017
P1, N=100, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Initiation date: Sep 2005 --> Dec 2005 N=66 --> 100
- | Emcyt (estramustine) / Pfizer, Nippon Shinyaku
Trial completion: SWOG-RTOG-P-0014: Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Mar 10, 2017
P3, N=21, Completed, Sponsor: Radiation Therapy Oncology Group
N=66 --> 100 Active, not recruiting --> Completed
- ||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment closed: BREACH: Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. (clinicaltrials.gov) - Mar 9, 2017
P2, N=170, Active, not recruiting, Sponsor: The Lymphoma Academic Research Organisation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Combination therapy: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). (clinicaltrials.gov) - Mar 9, 2017
P1/2, N=41, Completed, Sponsor: The Lymphoma Academic Research Organisation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=63 --> 41
- | Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. (clinicaltrials.gov) - Mar 9, 2017
P3, N=246, Completed, Sponsor: Gruppo Italiano Terapie Innovative nei Linfomi
Active, not recruiting --> Completed | N=63 --> 41 Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Mar 2013
- | Rituxan (rituximab) / Roche
Enrollment closed, Trial primary completion date: EU-MCL elderly: Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL (clinicaltrials.gov) - Mar 7, 2017
P3, N=570, Active, not recruiting, Sponsor: European Mantle Cell Lymphoma Network
Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Mar 2013 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2018
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Post-transplantation: PTLD-1/3: Risk Stratified Sequential Treatment for CD20-positive PTLD (clinicaltrials.gov) - Mar 7, 2017
P2, N=152, Completed, Sponsor: Charite University, Berlin, Germany
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2018 Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: VALFRID: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Mar 7, 2017
P1/2, N=50, Active, not recruiting, Sponsor: Lund University Hospital
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Mar 2018
- | carboplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=220, Recruiting, Sponsor: Loma Linda University
Trial primary completion date: Dec 2016 --> Mar 2018 Trial primary completion date: Jan 2017 --> Jan 2018
- | Trial completion: Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 6, 2017
P2, N=76, Completed, Sponsor: Stanford University
Trial primary completion date: Jan 2017 --> Jan 2018 Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg.
Journal: Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells. (Pubmed Central) - Mar 4, 2017
These results suggest that doxorubicin synergizes with cucurbitacin B in induction of cytotoxicity in anaplastic thyroid carcinoma cells. Moreover, synergistic cytotoxicity of doxorubicin with cucurbitacin B is mediated by B-cell chronic lymphocytic leukemia/lymphoma 2 family proteins, survivin, and reactive oxygen species and modulated by Janus kinase 2/signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2 in anaplastic thyroid carcinoma cells.
- | Rituxan (rituximab) / Roche
Trial primary completion date: Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 3, 2017
P2, N=194, Recruiting, Sponsor: National Cancer Institute (NCI)
Moreover, synergistic cytotoxicity of doxorubicin with cucurbitacin B is mediated by B-cell chronic lymphocytic leukemia/lymphoma 2 family proteins, survivin, and reactive oxygen species and modulated by Janus kinase 2/signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2 in anaplastic thyroid carcinoma cells. Trial primary completion date: Dec 2018 --> Feb 2021
- | Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma (clinicaltrials.gov) - Mar 3, 2017
P2, N=65, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2018 --> Feb 2021 Trial primary completion date: Feb 2017 --> Feb 2018
- | Emcyt (estramustine) / Pfizer, Nippon Shinyaku, Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer (clinicaltrials.gov) - Mar 3, 2017
P2, N=24, Recruiting, Sponsor: The University of Texas Health Science Center, Houston
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Feb 2017 --> Feb 2019
- ||| Jakafi (ruxolitinib) / Incyte
Trial initiation date: Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer (clinicaltrials.gov) - Mar 3, 2017
P2, N=64, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Feb 2017 --> Feb 2019 Initiation date: Aug 2016 --> Mar 2017
- | Enrollment open: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 3, 2017
P2, N=28, Recruiting, Sponsor: University of Washington
Initiation date: Aug 2016 --> Mar 2017 Not yet recruiting --> Recruiting
- | Enrollment open: Vaccination of High Risk Breast Cancer Patients (clinicaltrials.gov) - Feb 28, 2017
P1/2, N=61, Enrolling by invitation, Sponsor: University of Arkansas
Not yet recruiting --> Recruiting Active, not recruiting --> Enrolling by invitation
- |||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: KAITLIN: A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer (clinicaltrials.gov) - Feb 27, 2017
P3, N=1846, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Enrolling by invitation Trial primary completion date: Feb 2018 --> Jan 2024
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Enrollment change, Trial primary completion date: Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents (clinicaltrials.gov) - Feb 27, 2017
P1, N=4, Completed, Sponsor: Presage Biosciences
Trial primary completion date: Feb 2018 --> Jan 2024 Active, not recruiting --> Completed | N=12 --> 4 | Trial primary completion date: Nov 2015 --> Jul 2013
- | doxorubicin hydrochloride / Generic mfg.
Journal: Thermosensitive magnetic liposomes with doxorubicin-cell-penetrating peptides conjugate for enhanced and targeted cancer therapy. (Pubmed Central) - Feb 27, 2017
Additionally, in vivo study, DOX-CPPs/TSMLs under AC magnetic field displayed superior in vivo targeted delivery efficacy, antitumor efficacy in an MCF-7 xenograft murine model. In conclusion, the application of DOX-CPPs/TSMLs under AC magnetic field may provide a strategy for the selective and efficient delivery of drug.
- | Review, Journal: Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20. (Pubmed Central) - Feb 27, 2017
We opted to administer bendamustine with rituximab for a total of 6 cycles. She remains disease free 18 months after the completion of therapy.
- | Darzalex IV (daratumumab) / J&J
Clinical: 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy (clinicaltrials.gov) - Feb 27, 2017
P2, N=50, Not yet recruiting, Sponsor: University of Arkansas
She remains disease free 18 months after the completion of therapy. Initiation date: Jan 2017 --> May 2017
- | bortezomib / Generic mfg.
Trial primary completion date, Combination therapy: Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 24, 2017
P2, N=17, Recruiting, Sponsor: Stanford University
Initiation date: Jan 2017 --> May 2017 Trial primary completion date: Mar 2017 --> Sep 2017
- | Avastin (bevacizumab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date: Bevacizumab/Doxorubicin/Radiation for Sarcoma (clinicaltrials.gov) - Feb 24, 2017
P1, N=14, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Mar 2017 --> Sep 2017 Recruiting --> Active, not recruiting | N=18 --> 14 | Trial primary completion date: Jun 2017 --> May 2016
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Enrollment open, Gene therapy: Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov) - Feb 24, 2017
P=N/A, N=10, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | N=18 --> 14 | Trial primary completion date: Jun 2017 --> May 2016 Active, not recruiting --> Recruiting
- | Nerofe (84AA-API 14AA) / Immune System Key
New P2a trial, Combination therapy: A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS (clinicaltrials.gov) - Feb 23, 2017
P2a, N=22, Not yet recruiting, Sponsor: Immune System Key Ltd
- | Decadron (dexamethasone) / Merck (MSD)
Trial primary completion date: Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 23, 2017
P2, N=41, Recruiting, Sponsor: University of Iowa
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Jun 2017
- | doxorubicin hydrochloride / Generic mfg.
Phase classification, Surgery: MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Feb 23, 2017
P1, N=45, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2016 --> Jun 2017 Phase classification: P=N/A --> P1
- | minocycline extended release / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Biomarker, Journal: Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. (Pubmed Central) - Feb 23, 2017
Moreover, minocycline appeared to prevent the reduction in doublecortin-positive neural progenitor cells observed in AC-treated mice. We posit that minocycline may be useful clinically for its reported neuroprotective activity in breast cancer patients receiving AC without loss of chemotherapeutic efficacy.
- | doxorubicin hydrochloride / Generic mfg., vinblastine / Generic mfg.
Trial completion: SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease (clinicaltrials.gov) - Feb 20, 2017
P3, N=348, Completed, Sponsor: Southwest Oncology Group
We posit that minocycline may be useful clinically for its reported neuroprotective activity in breast cancer patients receiving AC without loss of chemotherapeutic efficacy. Active, not recruiting --> Completed
- alisertib (MLN8237) / Puma
Trial primary completion date: A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas (clinicaltrials.gov) - Feb 20, 2017
P1, N=24, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Sep 2020 --> May 2018